JP2025511401A - 癌を治療するための併用療法 - Google Patents

癌を治療するための併用療法 Download PDF

Info

Publication number
JP2025511401A
JP2025511401A JP2024559034A JP2024559034A JP2025511401A JP 2025511401 A JP2025511401 A JP 2025511401A JP 2024559034 A JP2024559034 A JP 2024559034A JP 2024559034 A JP2024559034 A JP 2024559034A JP 2025511401 A JP2025511401 A JP 2025511401A
Authority
JP
Japan
Prior art keywords
azd5305
acceptable salt
pharma
darolutamide
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559034A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023194528A5 (https=
JP2025511401A5 (https=
Inventor
キアーラ コスリッチ，サビーナ
エス ブラウン，ジェシカ
アール アルバーテラ，マーク
レオ，エリザベッタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2025511401A publication Critical patent/JP2025511401A/ja
Publication of JPWO2023194528A5 publication Critical patent/JPWO2023194528A5/ja
Publication of JP2025511401A5 publication Critical patent/JP2025511401A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024559034A 2022-04-07 2023-04-06 癌を治療するための併用療法 Pending JP2025511401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362612P 2022-04-07 2022-04-07
US63/362,612 2022-04-07
PCT/EP2023/059126 WO2023194528A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (3)

Publication Number Publication Date
JP2025511401A true JP2025511401A (ja) 2025-04-15
JPWO2023194528A5 JPWO2023194528A5 (https=) 2026-04-10
JP2025511401A5 JP2025511401A5 (https=) 2026-04-10

Family

ID=86185292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559034A Pending JP2025511401A (ja) 2022-04-07 2023-04-06 癌を治療するための併用療法

Country Status (11)

Country Link
US (1) US20250235448A1 (https=)
EP (1) EP4504180A1 (https=)
JP (1) JP2025511401A (https=)
KR (1) KR20240170956A (https=)
CN (1) CN118973572A (https=)
AU (1) AU2023248685A1 (https=)
CA (1) CA3254948A1 (https=)
IL (1) IL316016A (https=)
MX (1) MX2024012368A (https=)
TW (1) TW202404593A (https=)
WO (1) WO2023194528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026021478A1 (zh) * 2024-07-23 2026-01-29 江苏恒瑞医药股份有限公司 Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
MX2024012368A (es) 2024-11-08
AU2023248685A1 (en) 2024-11-14
CN118973572A (zh) 2024-11-15
IL316016A (en) 2024-11-01
TW202404593A (zh) 2024-02-01
US20250235448A1 (en) 2025-07-24
EP4504180A1 (en) 2025-02-12
KR20240170956A (ko) 2024-12-05
CA3254948A1 (en) 2023-10-12
WO2023194528A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
AU2013205648B2 (en) Combination treatment
TW202425976A (zh) 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
JP2025511401A (ja) 癌を治療するための併用療法
JP2025511402A (ja) 癌を治療するための併用療法
JP2025511403A (ja) 癌を治療するための併用療法
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
KR20260020107A (ko) 다발성 경화증을 치료하기 위한 btk 억제제
WO2025242217A1 (zh) 一种含噻吩并嘧啶化合物的药物组合物、其制备方法及用途
KR20240148328A (ko) 전이성 거세 저항성 전립선암 및 hrr 변형을 갖는 환자에서 임상 결과를 개선하기 위한 니라파립 및 아비라테론 아세테이트와 프레드니손
TW202600137A (zh) 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
CN118542942A (zh) Pd-l1小分子抑制剂与抗体的药物组合及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260402